Eyconis
CA - Redwood CityBiotechnology
Focus: Eyconis is a newly public biotechnology company focused on developing novel, best-in-class therapeutics for eye diseases, headquartered in Redwood City, CA. The company operates in the highly specialized ophthalmology segment with a lean, early-stage pipeline.
Profile data last refreshed 8h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
1
Should You Work at Eyconis?
AI assessmentEyconis is a speculative early-stage play best suited for risk-tolerant scientists seeking founding-team equity upside in a focused therapeutic area, not career stability.
Why Work Here
- Joining a newly public company (2024) offers early equity upside and opportunity to shape foundational organizational culture and processes
- Specialized focus on ophthalmology—a high-value therapeutic area with unmet medical needs and premium drug pricing potential
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Phase 1/2
Clinical Trials (1)
NCT07587515Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration
Phase 1/2Help build intelligence for Eyconis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.